번호 | 제목 | 첨부파일 | 등록일 | 조회 |
---|---|---|---|---|
52 | Risk Tool Selection With ICH Q9(R1) In Mind | 2023.10.13 | 524 | |
51 | FDA issues draft guidance on post-warning letter meetings under GDUFA... | 2023.10.13 | 514 | |
50 | 5 Best Practices For Responding To FDA Form 483 Inspection Observatio... | 2023.10.13 | 461 | |
49 | Cleanrooms: solving the mystery of recurring low level contamination | 2023.09.07 | 492 | |
48 | The possible Impact of Artificial Intelligence on the Role of the Qua... | 2023.09.07 | 434 | |
47 | Preparing A Framework For Artificial Intelligence And Machine Learnin... | 2023.09.07 | 539 | |
46 | CGMP Requirements For Automated Facility Monitoring Systems | 2023.09.07 | 477 | |
45 | RTU vs concentrate disinfectants: efficiency as a factor in selection | 2023.09.07 | 430 | |
44 | EMA phases out extraordinary COVID-19 regulatory flexibilities | 2023.08.09 | 363 | |
43 | 6 Ways To Achieve Manufacturing Audit And Inspection Readiness | 2023.08.09 | 497 |